Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis

Table 1 Baseline characteristics of the 131 study patients n (%)

Parameter	n
Age, yr, median (IQR)	41 (28-52)
Man/female	67/64
Disease duration, yr, median (IQR)	3.6 (2.0-10.1)
Actual disease extent
Proctitis	29 (22.2)
Left-sided colitis	24 (18.3)
Total colitis	76 (58.0)
Segmental colitis	2 (1.5)
Partial Mayo score
< 2	93 (71.0)
2-4	28 (21.4)
5-7	8 (6.1)
> 7	2 (1.5)
Laboratory data
WBC, /μL, median (IQR)	6525 (4838-8140)
CRP, mg/dL, median (IQR)	0.1 (0.04-0.20)
ESR, mm/h, median (IQR)	7 (4-11)
Albumin, g/dL, median (IQR)	4.3 (4.0-4.6)
Hemoglobin, g/dL, median (IQR)	13.6 (12.1-14.3)
Platelets, × 1000/μL, median (IQR)	268 (190-320)
FC, μg/g, median (IQR)	289 (78-785)
Medication
Mesalazine, oral	112 (85.5)
Mesalazine, topical	12 (9.2)
Immunomodulators	47 (35.9)
Anti-TNF	21 (16.0)
Corticosteroids	17 (13.0)

CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; FC: Fecal calprotectin; IQR: Interquartile range; TNF: Tumor necrosis factor; WBC: White blood cell.